Optima Health Secures First License for Digital Assessment Tool with NHS
Why we think this is good
The key factors that contribute to a "GOOD" sentiment score for this RNS are: - Optima Health has secured its first license contract for its proprietary DART tool with an NHS Trust, which represents a new market opportunity and sales pipeline for the company. - DART has been DTAC certified and listed on the NHS Innovation Service, indicating it meets the necessary standards for use in the NHS. - The successful four-month quality improvement study conducted with the NHS Trust demonstrated positive outcomes across various measures, including patient safety, pathway efficiency, cost savings, and patient and clinician satisfaction. - DART has received significant investment and development by Optima Health, with validation completed in association with a reputable university, leading to published papers in peer-reviewed journals. - The successful implementation of DART in the NHS Trust has created significant interest from other NHS musculoskeletal services, suggesting the potential for further growth and revenue.
Key Points
- Optima Health secures first license contract for its proprietary DART tool with Mersey & West Lancashire Teaching Hospitals NHS Trust
- DART is DTAC certified and listed on the NHS Innovation Service
- Successful four-month quality improvement study demonstrated positive outcomes across various measures
- DART has received significant investment and development by Optima Health, with academic validation
- Successful implementation of DART has created significant interest from other NHS services
Summary
Optima Health has secured its first license contract for its proprietary Digital Assessment Routing Tool (DART) with the Mersey & West Lancashire Teaching Hospitals NHS Trust. DART is a digital tool that assesses and routes patients to the correct type of care based on the urgency and complexity of their symptoms, following the "Getting It Right First Time" principle.
The successful four-month quality improvement study conducted with the NHS Trust demonstrated positive outcomes across various measures, including patient safety, pathway efficiency, cost savings, and patient and clinician satisfaction. DART has received significant investment and development by Optima Health, with validation completed in association with Queen Mary University of London, leading to published papers in international peer-reviewed journals.
The successful implementation of DART in the NHS Trust has created significant interest from other NHS musculoskeletal services, creating a new sales pipeline for Optima Health. While the immediate financial impact of the initial license contract is not quantified, this represents a new market opportunity and potential for future growth and revenue for the company.